Maraviroc, originally designated UK-427857, is a small molecule and the first oral antiretroviral drug in the CCR5 receptor antagonist class used in the treatment of HIV infection. This drug, classed as an entry inhibitor, was developed by the drug company Pfizer in its United Kingdom laboratory located in Sandwich. 

 

On April 24, 2007, the US Food and Drug Administration (FDA) advisory panel reviewing maraviroc’s new drug application, unanimously recommended approval for the new drug (1), and the drug received full FDA approval on August 6, 2007, for use in treatment experienced patients.